Morningstar

GSK Subsidiary Files Lawsuit Against AnaptysBio

Provided by Dow Jones

By Elena Vardon 




  Drugmaker GSK said it started litigation against AnaptysBio for what it called a material breach of an agreement regarding one of its cancer treatments. 



  GSK said its Tesaro subsidiary initiated the action, alleging that AnaptysBio breached a license agreement for the dostarlimab oncology treatment, commercialized as Jemperli. 



  According to GSK, AnaptysBio itself has alleged that Tesaro hadn't fulfilled some of the requirements of the agreement and that it intended to revoke it. GSK and Tesaro view these allegations are without merit, GSK said. 



  GSK said the alleged breach entitles Tesaro to terminate the current license agreement, get a perpetual and irrevocable license to dostarlimab, and cut the royalties and milestone payments to AnaptysBio by 50%. 



  AnaptysBio wasn't immediately available for comment. 





  Write to Elena Vardon at elena.vardon@wsj.com 





  (END) Dow Jones Newswires



  November 21, 2025 03:12 ET (08:12 GMT)


Copyright (c) 2025 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
What’s Ahead for Stocks This Quarter—and Where to Invest
 
Morningstar’s chief market strategist and economist share their outlooks for the fourth quarter of 2026. 
 
 
David Sekera, CFA, Preston Caldwell, and Susan Dziubinski 
 
 
 
5 Stocks to Sell for Tax-Loss Harvesting 
 
Plus, earnings season kicks off with big banks. 
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
Are TIPS ETFs the Best Way to Fight Inflation?
 
Plus, four TIPS ETFs with top marks from Morningstar, and what you need to know before investing. 
 
 
Daniel Sotiroff and Ivanna Hampton 
 
 
 
33 Undervalued Stocks to Buy Before the Market Shifts Again
 
Here’s the new list of Morningstar’s top analyst picks for the fourth quarter of 2026. 
 
 
Susan Dziubinski and Tori Brovet 
 
 
 
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
 
Even short-term muni funds aren’t totally immune from losses. 
 
 
Amy C. Arnott, CFA 
 
 
 
 

			Sponsor Center